Smoore CEO: Smoore Will Focus in Three Areas of Businesses

On the evening of August 24, 2022, Smoore International presented its results report for the first half of 2022, revealing an operating income of $5.65 billion and an adjusted net income of $1.44 billion. On August 25, Smoore issued a news release for 2022. Chen Zhiping, Vice President Qiu Lingyun, and Chief Financial Officer Wang Guisheng were present.

1. Business design layout

After the conference, 2 firsts obtained the meeting's key points and arranged them as follows.

During the question-and-answer session, Chen Zhiping stated that Smoore would continue to focus on the following businesses for quite some time: new tobacco, which is the company's primary source of revenue and a vast market; beauty; and Chinese traditional medicine. In Western medicine, lung disorders such as asthma and chronic obstructive pulmonary disease are treated. In Chinese medicine, lung diseases are studied.

2. Regarding annual performance objectives.

Smoore is bullish on the long-term growth outlook. Comparing the first half of the year to the second half, international markets have dramatically increased in revenue. Smoore's performance expectations for the second half of the year are higher than those for the first half.

3. international marketplaces

The European and American markets of Smoore will do better in the second half of the year than they did in the first. The European market is growing steadily, and the U.S. market will gain a competitive edge as a result of the FDA's regulatory clearance and the PMTA certification of the majority of Smoore's clients.

4. Pricing methodology

The company's product pricing strategy has not altered; nonetheless, low-margin items accounted for an increase in the first half. The growth in automated production lines enabled Smoore to lower their own expenses and client costs, resulting in a gross margin loss in the first half. However, the long-term gross margin is advantageous, and buyers will receive items that are more unique and competitive.

5. Medical Industry

Chen Zhiping said: "We have been active in medical care, including the Western treatment of lung ailments such as asthma and chronic obstructive pulmonary disease, as well as the study of Chinese traditional medicine. We came up with the notion of modernizing Chinese medicine by combining innovative technologies to breathe new life into traditional Chinese medicine texts and scientific procedures to demonstrate their efficacy."

Two years ago, Smoore began its planning for the medical health track. In China, Smoore's medical nebulized medication delivery system has completed the application for innovation certification, including product registration and sales planning, and is progressing in other respects. Simultaneously, Smoore has created in the United States a medical research center and a wholly-owned subsidiary.

6. Technical limitations

(1) Patents are the key to building technological obstacles for small businesses. Presently, there are 4,337 patent applications in Smoore's worldwide patent portfolio, with 929 new applications submitted in the first half of the year, mostly in four primary sectors, including aerosol production, different heat generating body technologies, medical fogging, and heating non-combustion, etc.

(2) Material and process research are Smoore's primary technological capabilities.

(3) Smoore expects that its technical invention can be developed into a comprehensive system (such as a heat emitter, material, manufacturing process, etc.) in order to increase its overall competitiveness.

(4) Talent barrier. Smoore has 14 fundamental research institutions in operation throughout the world in the first half of this year, as well as a number of prominent worldwide scientists, hundreds of graduates from famous colleges, and a large number of top management professionals. By the end of June, Smoore had 1,472 R&D specialists, representing nearly 40% of the entire workforce.